Literature DB >> 26873056

Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice.

Karen K Yam1, Jyotsana Gupta1, Elizabeth K Allen1, Kayla R Burt1, Édith Beaulieu2, Corey P Mallett2, David S Burt2, Brian J Ward3.   

Abstract

INTRODUCTION: There is great interest in developing more effective influenza vaccines for the elderly. Oil-in-water adjuvants can boost humoral responses to seasonal vaccines in elderly subjects but relatively little is known about their mechanism of action.
METHODS: We compared humoral and cellular immune profiles in young adult (2 months), mature (11-12 months) or aged (16-17 month) female BALB/c mice following two doses of Alum or AS03-adjuvanted A/H3N2 split-virus antigen (A/Uruguay/716/2007) at 0.75 or 3 μg hemagglutinin (HA) per dose intramuscularly versus 3 μg HA without adjuvant.
RESULTS: Overall, hemagglutination inhibition (HAI), microneutralization (MN) and end-point ELISA titres were higher in the young mice and when an adjuvant was used. Both adjuvants increased humoral responses in older animals but the highest titres across all groups were observed in the AS03-adjuvanted groups. Neither IgG avidity nor A/H3N2-specific splenocyte proliferation was influenced by age, antigen dose or adjuvant. In contrast, cytokine production by ex vivo-stimulated splenocytes differed widely between groups. Most cytokine levels in older mice vaccinated with antigen alone (3 μg HA/dose) were ≤ 50% of those in young animals. In young mice, cytokine levels increased modestly with Alum and significantly with AS03. Increases tended to be greatest at the lower antigen dose (0.75 μg versus 3 μg HA). In the older animals, Alum had little impact on cytokine production but responses in the AS03 groups paralleled those of the young mice (broad activation of Th1, Th2, and Th17-type cytokines) and the greatest increases were seen with the higher antigen dose (3 μg HA).
CONCLUSIONS: In both young and aged mice, Alum and AS03 increased the magnitude of humoral and cellular responses to split influenza virus vaccination. Overall, these effects were most pronounced in the younger animals and the groups receiving AS03. These data support the use of oil-in-water adjuvants in influenza vaccines targeting the elderly.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AS03; Adjuvant; Aged mice; Alhydrogel; Alum; Avidity; Chemokine; Cytokine; H3N2 virus; Hemagglutination inhibition; Immunosenescence; Influenza virus; Microneutralization; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 26873056     DOI: 10.1016/j.vaccine.2016.02.012

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.

Authors:  Karen K Yam; Angela Brewer; Virginie Bleau; Édith Beaulieu; Corey P Mallett; Brian J Ward
Journal:  Hum Vaccin Immunother       Date:  2016-10-21       Impact factor: 3.452

Review 2.  Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs.

Authors:  Santosh Dhakal; Sabra L Klein
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

3.  Inflammatory responses to influenza vaccination at the extremes of age.

Authors:  Jacqueline U McDonald; Ziyun Zhong; Helen T Groves; John S Tregoning
Journal:  Immunology       Date:  2017-05-16       Impact factor: 7.397

4.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

5.  A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response.

Authors:  Breanna Hodgins; Karen K Yam; Kaitlin Winter; Stephane Pillet; Nathalie Landry; Brian J Ward
Journal:  Clin Vaccine Immunol       Date:  2017-12-05

6.  Immunosenescence-Related Transcriptomic and Immunologic Changes in Older Individuals Following Influenza Vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Iana H Haralambieva; Ann L Oberg; Michael T Zimmermann; Diane E Grill; Gregory A Poland
Journal:  Front Immunol       Date:  2016-11-02       Impact factor: 7.561

7.  A Pre-Clinical Safety Evaluation of SBP (HBsAg-Binding Protein) Adjuvant for Hepatitis B Vaccine.

Authors:  Jingbo Wang; Caixia Su; Rui Liu; Baoxiu Liu; Inam Ullah Khan; Jun Xie; Naishuo Zhu
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

8.  Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis.

Authors:  Yu-Ju Lin; Yun-Jui Shih; Chang-Hsun Chen; Chi-Tai Fang
Journal:  Sci Rep       Date:  2018-07-30       Impact factor: 4.379

9.  Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models.

Authors:  Ricardo Choque-Guevara; Astrid Poma-Acevedo; Ricardo Montesinos-Millán; Dora Rios-Matos; Kristel Gutiérrez-Manchay; Angela Montalvan-Avalos; Stefany Quiñones-Garcia; Maria de Grecia Cauti-Mendoza; Andres Agurto-Arteaga; Ingrid Ramirez-Ortiz; Manuel Criollo-Orozco; Edison Huaccachi-Gonzales; Yomara K Romero; Norma Perez-Martinez; Gisela Isasi-Rivas; Yacory Sernaque-Aguilar; Doris Villanueva-Pérez; Freddy Ygnacio; Katherine Vallejos-Sánchez; Manolo Fernández-Sánchez; Luis A Guevara-Sarmiento; Manolo Fernández-Díaz; Mirko Zimic
Journal:  PLoS One       Date:  2022-08-23       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.